A phase I/II study of pixantrone (BBR 2778) in patients with refractory acute myelogenous leukemia (AML)
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2014
At a glance
- Drugs Pixantrone (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors CTI BioPharma
- 21 Aug 2007 Status change from in progress to completed.
- 26 Jul 2007 The expected completion date for this trial is now 1 Mar 2007.
- 22 Aug 2006 Status change